IL276836A - Cd83-binding chimeric antigen receptors - Google Patents

Cd83-binding chimeric antigen receptors

Info

Publication number
IL276836A
IL276836A IL276836A IL27683620A IL276836A IL 276836 A IL276836 A IL 276836A IL 276836 A IL276836 A IL 276836A IL 27683620 A IL27683620 A IL 27683620A IL 276836 A IL276836 A IL 276836A
Authority
IL
Israel
Prior art keywords
chimeric antigen
antigen receptors
binding chimeric
binding
receptors
Prior art date
Application number
IL276836A
Other languages
English (en)
Hebrew (he)
Original Assignee
H Lee Moffitt Cancer Ct & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Ct & Res filed Critical H Lee Moffitt Cancer Ct & Res
Publication of IL276836A publication Critical patent/IL276836A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL276836A 2018-02-23 2020-08-20 Cd83-binding chimeric antigen receptors IL276836A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862634435P 2018-02-23 2018-02-23
US201862677783P 2018-05-30 2018-05-30
PCT/US2019/019065 WO2019165156A1 (en) 2018-02-23 2019-02-22 Cd83-binding chimeric antigen receptors

Publications (1)

Publication Number Publication Date
IL276836A true IL276836A (en) 2020-10-29

Family

ID=67686942

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276836A IL276836A (en) 2018-02-23 2020-08-20 Cd83-binding chimeric antigen receptors

Country Status (14)

Country Link
US (1) US12492254B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755722A4 (cg-RX-API-DMAC7.html)
JP (1) JP7358369B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200130324A (cg-RX-API-DMAC7.html)
CN (1) CN112004832A (cg-RX-API-DMAC7.html)
AU (1) AU2019226101A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020017015A2 (cg-RX-API-DMAC7.html)
IL (1) IL276836A (cg-RX-API-DMAC7.html)
MA (1) MA51917A (cg-RX-API-DMAC7.html)
MX (1) MX2020008803A (cg-RX-API-DMAC7.html)
PH (1) PH12020500632A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007755YA (cg-RX-API-DMAC7.html)
WO (1) WO2019165156A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202005837B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492254B2 (en) 2018-02-23 2025-12-09 H. Lee Moffitt Cancer Center and Research Intitute. Inc. CD83-binding chimeric antigen receptors
CA3147835A1 (en) * 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute Inc. Chimeric antigen receptors for treating myeloid malignancies
EP4013447A4 (en) * 2019-08-16 2024-05-29 H. Lee Moffitt Cancer Center & Research Institute, Inc. T CELLS EXPRESSING A CHIMERIC ANTI-CD83 ANTIGEN RECEPTOR
US11802159B2 (en) * 2019-09-30 2023-10-31 The Trustees Of The University Of Pennsylvania Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs)
US20230051885A1 (en) * 2019-12-18 2023-02-16 H. Lee Moffitt Cancer Center And Research Institute Inc. Systems and Methods for Producing Efficacious Regulatory T Cells
WO2021150970A1 (en) * 2020-01-22 2021-07-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor
WO2021168421A1 (en) * 2020-02-20 2021-08-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of enhancing immunotherapy using er stress pathway inhibitors
WO2022036224A1 (en) * 2020-08-14 2022-02-17 H. Lee Moffitt Cancer Center And Research Institute Inc. Chimeric antigen receptor t cells for treating autoimmunity
WO2022183160A1 (en) * 2021-02-25 2022-09-01 H. Lee Moffitt Cancer Center And Research Institute Inc. Methods for treating cd83-expressing cancer
WO2022260909A1 (en) * 2021-06-09 2022-12-15 H. Lee Moffitt Cancer Center And Research Institute Inc. Methods of using anti-cd83 chimeric antigen receptor expressing t cells
CN119331093B (zh) * 2024-11-04 2025-07-11 武汉伊莱瑞特生物科技股份有限公司 一种抗CD30的兔源Fab抗体及其制备方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
EP1572976B1 (en) 2002-11-21 2010-09-15 Celltech R & D, Inc. Modulating immune responses
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
WO2009155477A1 (en) 2008-06-19 2009-12-23 The Trustees Of The University Of Pennsylvania Inducible regulatory t-cell generation for hematopoietic transplants
CN104906139B (zh) 2011-01-10 2020-10-23 小利兰·斯坦福大学托管委员会 异源造血干细胞移植的增强
JP2013150592A (ja) * 2011-07-01 2013-08-08 Genentech Inc 自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
AU2014213009B2 (en) * 2013-02-01 2019-01-03 Kira Biotech Pty Limited Anti-CD83 antibodies and use thereof
AU2014223602C1 (en) 2013-02-26 2018-11-08 Axiomx, Inc. Methods for the production of libraries for directed evolution
CA2923553C (en) 2013-09-13 2023-05-23 Soligenix, Inc. Novel peptides and analogs for use in the treatment of oral mucositis
AU2015336931B2 (en) * 2014-10-23 2021-04-29 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
PL3212225T3 (pl) * 2014-10-31 2026-03-30 The Trustees Of The University Of Pennsylvania Sposoby i kompozycje zmodyfikowanych limfocytów t
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
AU2016274989A1 (en) 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
TWI833684B (zh) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
SG11201807489PA (en) * 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CA3042613A1 (en) 2016-11-11 2018-05-17 Autolus Limited Chimeric antigen receptor
KR20200066613A (ko) 2017-09-13 2020-06-10 키라 바이오테크 피티와이 리미티드 치료 방법
CA3076337A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
WO2019136335A1 (en) 2018-01-05 2019-07-11 Gencyte Therapeutics, Inc. Precision molecular adaptor system for car-t immunotherapy
ES3012854T3 (en) 2018-02-08 2025-04-10 Univ Leland Stanford Junior Allogenic hematopoietic stem cell transplantation
US20200108098A1 (en) 2018-02-23 2020-04-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Anti-cd83 chimeric antigen receptor expressing t regulatory cells
US12492254B2 (en) 2018-02-23 2025-12-09 H. Lee Moffitt Cancer Center and Research Intitute. Inc. CD83-binding chimeric antigen receptors
US20200268797A1 (en) 2018-11-30 2020-08-27 Janssen Biotech, Inc. Gamma delta t cells and uses thereof
EP4013447A4 (en) 2019-08-16 2024-05-29 H. Lee Moffitt Cancer Center & Research Institute, Inc. T CELLS EXPRESSING A CHIMERIC ANTI-CD83 ANTIGEN RECEPTOR
US20230051885A1 (en) 2019-12-18 2023-02-16 H. Lee Moffitt Cancer Center And Research Institute Inc. Systems and Methods for Producing Efficacious Regulatory T Cells
WO2021150970A1 (en) 2020-01-22 2021-07-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor
US20250052748A1 (en) 2021-12-22 2025-02-13 Regents Of The University Of Minnesota Cd83 and allo- and autoimmune conditions
JP2024102735A (ja) 2023-01-19 2024-07-31 セイコーエプソン株式会社 頭部装着型表示装置及び光学ユニット

Also Published As

Publication number Publication date
MA51917A (fr) 2021-06-02
US20210032336A1 (en) 2021-02-04
AU2019226101A1 (en) 2020-09-17
US12492254B2 (en) 2025-12-09
BR112020017015A2 (pt) 2020-12-15
SG11202007755YA (en) 2020-09-29
JP7358369B2 (ja) 2023-10-10
EP3755722A4 (en) 2021-11-24
JP2021513857A (ja) 2021-06-03
PH12020500632A1 (en) 2021-05-10
CN112004832A (zh) 2020-11-27
EP3755722A1 (en) 2020-12-30
ZA202005837B (en) 2023-02-22
CA3092220A1 (en) 2019-08-29
MX2020008803A (es) 2021-01-15
KR20200130324A (ko) 2020-11-18
WO2019165156A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
IL280029A (en) Ror-1 specific chimeric antigen receptors and uses thereof
IL280033A (en) Uses of anti-bcma chimeric antigen receptors
IL281428A (en) Chimeric antigen receptor
IL281097A (en) Chimeric antigen receptors against multiple hla-g isoforms
IL280003A (en) Anti-mesothelin antibodies
KR102763158B9 (ko) 최적화된 항tl1a 항체
IL263220A (en) Cd33 specific chimeric antigen receptors
IL282668A (en) Humanized antibodies against c-kit
IL269531A (en) Improved antigen binding receptors
EP3797122A4 (en) Anti-ror antibody constructs
IL285909A (en) Anti-bcma chimeric antigen receptors
IL259120B (en) Chimeric antigen receptors targeting her2
IL258502A (en) Chimeric antigen receptors targeted to psca
EP3999550A4 (en) ANTI-DLL3 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
EP3849598A4 (en) ANTI-TREM-2 AGONIST ANTIBODIES
EP3580212A4 (en) REGULATION OF CHEMERIC ANTIGEN RECEPTORS
IL251030B (en) Chimeric antigen receptors
DK3806903T5 (da) Cd79a kimæriske antigenreceptorer
ZA202005837B (en) Cd83-binding chimeric antigen receptors
PL3274366T3 (pl) Chimeryczny receptor antygenowy
PT3286223T (pt) Recetores de antigénio quimérico do antigénio do mieloma kappa e suas utilizações
EP3604344A4 (en) CHIMERIC ANTIGEN RECEPTOR
DK3452513T3 (da) Humaniserede anti-il-ir3-antistoffer
IL289899A (en) Anti-hk2 chimeric antigen receptor (car)
EP3763743A4 (en) BISPECIFIC ANTIBODY